News briefs: Japan clears filgrastim biosimilar; GSK to up stake in Nigerian and Indian firms; UCB deals

26 November 2012

Mid-sized Japanese drugmaker Mochida Pharmaceutical (TYO: 4534) says that it has received marketing authorization from Japan’s Ministry of Health, Labor and Welfare for filgrastim, which is co-developed by Fuji Pharma, a division of Fujifilm.

Mochida and Fuji Pharma filed for approval of the product in December 2011, under a 2010 development agreement between the companies. Filgrastim will become the first biosimilar granulocyte colony-stimulating factor (G-CSF) to be marketed in Japan. Biosimilars of Amgen’s leukemia drug Neupogen (filgrastim) are already approved in the USA and European Union (The Pharma Letters passim).

GlaxoSmithKline offer to increase stakes in Nigerian and Indian affiliates

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK